Cargando…
A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD
The long-term use of inhaled anticholinergic agents has recently been suggested to be associated with an excess risk of adverse cardiovascular (CV) outcomes in patients with COPD. We identified 15 published studies that reported on the association between long-term inhaled anticholinergic use and ad...
Autores principales: | Hilleman, Daniel E, Malesker, Mark A, Morrow, Lee E, Schuller, Dan |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719255/ https://www.ncbi.nlm.nih.gov/pubmed/19657399 |
Ejemplares similares
-
Management of patients with fibrosing interstitial lung diseases
por: Morrow, Lee E, et al.
Publicado: (2021) -
Safety and tolerability of inhalational anticholinergics in COPD
por: Sharafkhaneh, Amir, et al.
Publicado: (2013) -
Potential Benefits of Icosapent Ethyl on the Lipid Profile: Case Studies
por: Hilleman, Daniel E., et al.
Publicado: (2014) -
The development of anticholinergics in the management of COPD
por: Scullion, Jane E
Publicado: (2007) -
Bronchodilators in COPD: Impact of β-agonists and anticholinergics on severe exacerbations and mortality
por: Salpeter, Shelley R
Publicado: (2007)